Skip to content
DataLookout
Menu

NCT06716203

A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 10 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Nov 14, 2026 Show 5 more changesShow less
    • Start date: Dec 2, 2024 to Jan 3, 2025
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Site details revised
  2. Minor Start date changed from estimate of Dec 1, 2024 to Dec 2, 2024v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change From Baseline in Hemoglobin A1c (HbA1c)
Timeframe: Week 0 to Week 32

Secondary (5)

Change From Baseline in Body Weight
Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of Participants With HbA1c Target Value of <7%
Percentage of Participants With HbA1c Target Value of <5.7%
Change From Baseline in Fasting Serum Glucose

Arms and interventions

Experimental: 5 mg BGM0504Experimental

Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

Experimental: 10 mg BGM0504Experimental

Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.

Placebo Comparator: PlaceboPlacebo comparator

Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.

Drugs: Drug: 5 mg BGM0504 Administered SC, Drug: : 10 mg BGM0504 Administered SC, Drug: Placebo Administered SC

Sites

1 site in 1 country

  • Peking University People's HospitalBeijing, Beijing Municipality, China